Lundbeck Raises 2026 Revenue and EBITDA Guidance

The Danish brain health company lifted its full-year growth outlook at constant exchange rates on November 10, 2026.

Updated on Nov. 10, 2026 in Corporate Finance

Bold flat-color editorial illustration of an ascending stack of pale-blue tablets beside an empty blister card on a deep navy field.
Danish brain-health company Lundbeck raised its 2026 revenue growth guidance to 11% to 12%, citing strong U.S. sales of migraine drug Vyepti. AI Illustration. Upload story photo >

H. Lundbeck A/S raised its 2026 total revenue growth guidance to 11% to 12% at constant exchange rates, up from 7% to 9%. The company also increased its adjusted EBITDA growth guidance to 15% to 19%, from 8% to 14%.

Why it matters

The upgrade signals stronger-than-expected commercial performance for a biopharmaceutical company focused exclusively on brain health. Lundbeck attributed the revised outlook primarily to continued strong sales of Vyepti in the U.S. and better-than-expected results from its Partner Markets.

Lundbeck's revised 2026 guidance lifts revenue growth at constant exchange rates to 11% to 12%, from 7% to 9%, and adjusted EBITDA growth to 15% to 19%, from 8% to 14%. The full assumptions behind these ranges will appear in the financial report for January 1 to September 30, 2026.

The players

H. Lundbeck A/S

A Danish biopharmaceutical company headquartered in Valby, Denmark, focused exclusively on brain health and sold in more than 80 countries.

The details

Lundbeck, headquartered in Valby, Denmark, announced the revised guidance in a company announcement dated November 10, 2026, disclosed as inside information under Article 17 of the EU Market Abuse Regulation. The company expects 2026 R&D investments of approximately DKK 5.6 to 5.7 billion.

Timeline

  1. January 1, 2026 to September 30, 2026: period covered by the forthcoming financial report underlying the guidance.

  2. November 10, 2026: Lundbeck announces the raised 2026 financial guidance.

Market Dynamics

The guidance raise was published as inside information under Article 17 of the EU Market Abuse Regulation, which requires listed companies to disclose price-sensitive developments promptly. Lundbeck's upgrade thus arrives through the formal disclosure channel that governs European listed-company guidance changes.

Investors holding Lundbeck shares now have a higher revenue and EBITDA growth outlook to weigh against the company's R&D spending of roughly DKK 5.6 to 5.7 billion this year. Details behind the revised ranges will be set out in the financial report covering January through September 2026.

The takeaway

Raised guidance from a company with a clear focus on one therapeutic area suggests its commercial products are outperforming earlier expectations. Readers tracking the stock should watch the upcoming nine-month financial report for the assumptions behind the new ranges.

Further reading

Explore more Corporate Finance coverage for context on how companies communicate guidance changes to investors.